Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 02 May 2017 | By Zachary Brennan
Setting the stage for a likely exodus from the UK for pharmaceutical manufacturers and staff, the European Medicines Agency (EMA) on Tuesday notified marketing authorization holders (MAHs) that for centrally authorized products, EU law requires them to be established in the EU or European Economic Area, which includes Iceland, Liechtenstein and Norway.
EMA also notified MAHs that some of their activities must be performed in the EU (or EEA), related for example to pharmacovigilance and batch release, among others.
“Preparing for the withdrawal is therefore not just a matter for European and national administrations, but also for private parties,” EMA said. “Marketing authorisation holders may be required to adapt processes and to consider changes to the terms of the marketing authorisation in order to ensure its continuous validity and exploitation, once the United Kingdom has left the Union.”
In addition, EMA and the European Commission said they expect MAHs to prepare and proactively screen authorized medicines for any necessary changes.
“The necessary transfer or variation requests will need to be submitted in due time considering the procedural timelines foreseen in the regulatory framework,” EMA said. “Marketing authorisation holders will need to act sufficiently in advance to avoid any impact on the continuous supply of medicines for human and veterinary use within the European Union.”
The medicines agency last week also noted that they are planning their own workload shift to fill gaps when UK experts no longer work with EMA.
EMA spokesperson Ester Arauzo Azofra told Focus via email on Tuesday that no date has been set yet for EMA’s departure from London, “but there is a shared understanding that this needs to be settled rapidly.”
Notice to marketing authorisation holders of centrally authorised medicinal products for human and veterinary use
EMA on United Kingdom’s withdrawal from the European Union
Tags: Brexit, pharmaceutical companies in UK, MAHs in UK
Regulatory Focus newsletters
All the biggest regulatory news and happenings.